Effects of CCFM1214 and CCFM1215 on halitosis: a double-blind, randomized controlled trial.

The purpose of this study was to evaluate the effects of known probiotic species CCFM1214 and CCFM1215 on halitosis, the oral status, and the oral microbiome. In a double-blind, randomized controlled trial that lasted for five weeks, 43 participants were divided into an oral probiotics group and a control group and given probiotics or control powder for the first four weeks, with the fifth week being the discontinuation period. 33 participants (probiotics group = 21, control group = 12) completed the entire experiment in the end. Oral samples were taken as part of oral health examinations during the baseline period (day 0) and four weeks after (day 28). The nucleotide sequence of the V3-V4 region of 16S rRNA was determined to examine the impact of intervention and time on the oral microbiome. The effects of CCFM1214 and CCFM1215 on the number of in gingival crevicular fluid (GCF) samples of participants were detected by quantitative PCR. After the intervention, CCFM1214 and CCFM1215 significantly reduced the levels of volatile sulfur compounds (VSCs) and the quantity of in GCF samples, where the average DNA copy number per ng (log) of decreased from 7.12 ± 0.04 to 6.01 ± 0.09. The β diversity of the probiotics group, on the whole, tended to be more concentrated and stable after the intervention. In addition, after probiotic intervention, the abundance of and increased, while the abundance of , , , and decreased significantly. In general, CCFM1214 and CCFM1215 can alleviate halitosis and considerably lower the value of VSCs and improve the oral microbiota in participants with halitosis.